Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0023890 (cirrhosis)
 42,195 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

A change in erythrocyte osmotic fragility was observed on various liver diseases by means of the coil planet centrifuge (CPC) system, and the relationship between changes in it and in serum lipids was studied. According to the CPC classification of hemolytic patterns of L, M, T and R, the frequency of appearance of T and R increased in liver cirrhosis and primary hepatoma. Hemolytic start and end points both changed considerably in primary hepatoma, acute hepatitis and liver cirrhosis. Change of hemolytic end point which shifted to the hypotonic side is more prominent than that of hemolytic start point. The hemolytic end point showed an inverse correlation to serum alkaline phosphatase and LAP, and correlation to pseudocholinesterase and albumin. Among the relations of red cell fragility and lipids of the lipoprotein fractions, free cholesterol and the ratio of free cholesterol to phospholipid in high density lipoprotein were both in remarkable inverse correlation to the hemolytic end point. Free cholesterol in high density lipoprotein was concluded one of the most important determinants of erythrocyte osmotic fragility.
 ...
PMID:Erythrocyte osmotic fragility in various liver diseases--application of coil planet centrifuge system. 626 80

This paper was designed to study experimentally in rats hepatic and serum pseudocholinesterase, (CHE), and its isoenzyme activity, and also to analyze its behavior in acute hepatitis, cirrhosis and primary and secondary hepatic tumours. Five isoenzymes in rat liver homogenates and 4 to 5 in rat serum were found. In normal human serum 4 to 5 CHE-isoenzymes were recognized. Cuali and quantitative decreases in all serum CHE isoenzymes were found in all patients with severe liver disease. Isoenzyme No. 1 decreased significatively in cirrhotics, showing a double peak inscription. Isoenzyme No. 5 was elevated in the three patients with hepatoma.
 ...
PMID:[Usefulness of serum pseudocholinesterase isoenzymes in acute and chronic liver diseases and neoplasms (experimental and clinical study)]. 627 51

When compared to values obtained in normalweight, normolipidemic control subjects, the level of complement C3 protein and total complement activity (CH50) were found to be obviously decreased in patients with decompensated cirrhosis of the liver and slightly but significantly increased in subjects with type IIb and type IV hyperlipoproteinemia. C3 protein level was positively correlated with the concentration of serum cholesterol, the logarithm of serum triglyceride concentration, serum pseudocholinesterase and total complement activity. There were no significant differences concerning C3 protein level between hyperlipidemic subjects with clinical atherosclerosis and those without documented vascular disease. It is suggested that accelerated lipoprotein turnover occurring in many subjects with type IIb and type IV hyperlipoproteinemia might enhance the synthesis of several liver produced plasma enzymes and proteins including the C3 protein of the complement system.
 ...
PMID:Increased level of the complement C3 protein in endogenous hypertriglyceridemia. 710 36

When compared to values obtained in healthy normolipidemic normal weight control subjects, the plasma antithrombin III level determined by immunological, clotting and thrombin-agarose diffusion techniques was found to be obviously decreased in patients with decompensated cirrhosis of the liver and slightly but significantly increased in hyperlipidemic and especially in hypertriglyceridemic subjects. Plasma antithrombin III was positively correlated with serum cholesterol level, the logarithm of serum triglyceride concentration and serum pseudocholinesterase activity. A weaker correlation between plasma fibrinogen and antithrombin III was noted in the investigated clinical material. It is suggested that the accelerated fatty acid and lipoprotein turnover occurring in many subjects with type IIb and type IV hyperlipoproteinemia might be accompanied by an enhanced hepatic protein synthesis involving various liver secretion enzymes and clotting factors as well as antithrombin III.
 ...
PMID:Increased plasma antithrombin III level in hyperlipidemic subjects. 722 27

Following an introduction on the question of pseudocholinesterase (CHE) in cirrhosis of the liver and acute and chronic hepatopathy, a personal study of 35 chronic cases at various stages of the disease is reported. The patients were submitted to the usual haematochemical liver function tests as well as to liver needle biopsy with anatomo-functional staging of the liver trouble, which was largely due to alcohol poisoning. The CHE level in these patients was monitored until death. On the basis of the results, measurement of CHE is identified as an index not only of liver function (this is of course well known) but of prognosis infausta, there being a confirmed correlation between survival and CHE serum level.
 ...
PMID:[Serum levels of pseudocholinesterase in alcoholic cirrhosis patients. Correlation with the extent of anatomo-functional damage. Unfavorable prognostic index]. 731 40

The concentrations of platelet-derived growth factor in serum in 7 healthy controls (61 +/- 9 years; mean +/- SD) and 10 patients (62 +/- 8 years) with chronic liver disease (chronic hepatitis and/or liver cirrhosis) were compared. The plasma concentration of platelet-derived growth factor was below the detection limit (< 0.45 microgram/l) in all the subjects studied. The peripheral blood platelet count in patients with chronic liver disease was significantly lower than that in control subjects. However, the concentration of platelet-derived growth factor in serum, which was assumed to be released from platelet, was similar in patients with chronic liver disease and control subjects. These results indicate that the mean amount of platelet-derived growth factor released from the same number (10(9)) of platelets, calculated from the serum platelet-derived growth factor concentration and the peripheral blood platelet count, in patients with chronic liver disease (33 +/- 11 ng/10(9) platelets) was significantly (p < 0.01) higher than that in control subjects (14 +/- 5 ng/10(9) platelets). Moreover, the amount of platelet-derived growth factor released from 10(9) platelets inversely correlated with the serum concentration of pseudocholinesterase activity (r = -0.65, p < 0.01), and correlated positively (r = 0.91, p < 0.01) with the percent retention of indocyanine green in serum, in all subjects studied. These findings suggest that the amount of platelet-derived growth factor releasable from platelets of patients with chronic liver disease is higher than that in normal subjects and that it correlates with the severity of the disease.(ABSTRACT TRUNCATED AT 250 WORDS)
 ...
PMID:Increased release of platelet-derived growth factor from platelets in chronic liver disease. 816 96

Assessment of hepatic function is based on both liver blood tests and functional tests, the extensive application of which is still controversial. The aim of this study was to evaluate the clinical utility of a few selected tests as discriminatory and prognostic indexes: serum albumin, pseudocholinesterase, prothrombin time, as well as galactose elimination capacity and hepatic sorbitol clearance. Two separate studies were performed: Study I to investigate how well these tests assessed severity, and Study II to evaluate their prognostic value. A total of 128 consecutive cirrhotic patients classified according to the Child-Pugh score were included in Study I; Study II was carried out on 47 of these 128 during a two-year follow-up period. Pairwise correlations between all tests and Child-Pugh score yielded higher significant values for liver blood tests than for the functional ones. In Study I functional tests such as galactose elimination capacity and hepatic sorbitol clearance did not appear to be better than conventional biochemical tests in discriminating clinical severity of cirrhotic patients, as defined by Child-Pugh classification. Results of Study II confirmed that in severe liver cirrhosis Child-Pugh score remains the best method for medium- and long-term prognosis and for planning liver transplantation. Functional tests should be reserved for defining the residual functioning liver mass or for studies about functional liver plasma flow.
 ...
PMID:Evaluation of hepatic function in liver cirrhosis: clinical utility of galactose elimination capacity, hepatic clearance of D-sorbitol, and laboratory investigations. 1021 39

This paper records biochemical and follow-up observations on 153 patients with cirrhosis who have had a shunt operation. The experience confirms that no shunt operation should be undertaken on a patient whose serum albumin level is less than 3.2g.%. Low pseudocholinesterase levels are of help diagnostically but the main value of this test is in indicating whether or not liver function will deteriorate after a shunt operation in any given patient.
 ...
PMID:Serum albumin, pseudocholine-sterase, and transaminases in the assessment of liver function before and after venous shunt operations. 1371 37


<< Previous 1 2